Expert panel 2014 · ERA-EDTA 2014 · AHA/Salt-guideline 2024

The Inpatient Hyponatremia Journey

Five prototype admissions — from seizure in the ED to a cirrhotic with refractory ascites. Click any stage to expand the guideline detail and physiology reasoning.

Stage 1 · Presentation

The Seizing Patient — First 5 Minutes in the ED

A 34-year-old woman is brought by EMS after a witnessed generalized tonic-clonic seizure at a marathon finish line. Postictal, disoriented, GCS 11. Bedside glucose 92. Temperature normal. The triage nurse asks for orders before labs return.

Click to expand the bedside reasoning ↓

Bedside reasoning · Think "water" A young, previously healthy athlete who seizes mid- or post-race with a normal glucose and no head trauma is hyponatremic until proven otherwise. Exercise-associated hyponatremia (EAH) is the single most important cause of death in recreational endurance athletes — almost always from hypotonic overdrinking plus exercise-driven non-osmotic ADH release. The treatment window is measured in minutes, not hours.

Airway / Breathing: Recovery position, suction secretions, 2 L/min O₂ via NC while assessing. Intubate only if GCS remains ≤8 after the postictal phase or airway is compromised — most patients protect their airway once the acute tonic-clonic phase is over.
IV access: Two large-bore peripheral IVs. Do NOT start maintenance fluids empirically. If any fluid is flowing before the sodium is known, make it normal saline at a keep-vein-open rate; hypotonic fluids (D5W, ½ NS) can worsen hyponatremia catastrophically.
Labs to send: BMP (the Na is the point), serum osmolality, paired urine osm + urine Na + urine K, TSH, random cortisol, CK, lactate, venous blood gas, UDS, ethanol, β-hCG. Ask the chemistry lab to rush the sodium (verbal result within 10 minutes).
Bedside history (partners / bystanders): How much water did she drink? Any sports drinks or pickle juice? Any medications (SSRIs, MDMA, oxcarbazepine, thiazides)? Menstruating? Recent surgery (post-op hyponatremia peaks day 1–3)? Any seizure history?
Pre-verbal-result orders that are safe: Neuro checks every 15 min, continuous pulse ox + cardiac monitor, IV lorazepam 2 mg for recurrent seizure, no free water PO, hold any sips until Na is known.

Why athletes get this Exercise causes non-osmotic ADH release from the hypothalamus (driven by vasopressinergic signals from pain, stress, nausea, and heat). At the same time, "hydration" messaging has told marathoners to "drink ahead of thirst." The result: ADH-mediated water retention meets voluntary polydipsia. Add a pre-race SSRI and a post-race NSAID (which potentiates ADH) and Na can fall 15 mEq/L in under 2 hours.

Stage 2 · Labs Back

Na 118 — Recognising an Acute, Symptomatic Hyponatremia

The chemistry analyser flags the sodium. The chart now shows a value that, alone, demands action — but the tempo of the drop and the neurological picture, not the absolute number, decide the dose.

Click to expand the lab panel and framework ↓

Critical labs — 14:42

Na118 mEq/L

K3.6 mEq/L

Cl86

HCO₃22

Cr0.7 mg/dL

Glucose92 mg/dL

Serum osm (measured)247 mOsm/kg

Urine osm412 mOsm/kg

Urine Na58 mEq/L

TSH · Cortisolpending

Expert panel 2014 · Severe symptoms Severe symptoms of hyponatremia = seizure, coma (GCS ≤8), respiratory arrest, or deep somnolence. These define a medical emergency regardless of the sodium number. Treatment is 100 mL 3% NaCl bolus over 10 min, up to three times, aiming for a 4–6 mEq/L rise within the first hour. That 4–6 mEq rise is usually enough to stop seizures and reduce herniation risk.

Acute vs chronic — the single most important question A drop over <48 h = acute; the brain has not yet exported organic osmolytes, so cerebral edema dominates and aggressive correction is safe and necessary. A drop over >48 h (or of unknown duration) = treat as chronic; the brain has adapted by shedding osmolytes, so the correction rate ceiling (≤8 mEq/L per 24 h, or ≤10 by some guidelines) must be respected to avoid osmotic demyelination. In this runner, the marathon started 5 hours ago and she was well at the start line — so this is acute. Correct to stop the seizure, then clamp.

Serum osm interpretation: Measured 247 mOsm/kg = true hypotonic hyponatremia. Hyperglycemia, mannitol, glycine (TURP syndrome), and hypertonic contrast cause translocational hyponatremia with high osm — excluded here. Pseudohyponatremia (marked hypertriglyceridemia or paraproteinemia) gives a normal measured osm — also excluded.
Urine osm 412 mOsm/kg: ADH is fully "on." In pure primary polydipsia, the kidney can dilute urine to <100 mOsm/kg. A urine osm this high in the face of a serum osm of 247 proves that ADH is inappropriately active — exactly what exercise-associated, post-op, and SIADH-pattern physiology produces.
Urine Na 58: Suggests the kidney is not avidly conserving Na — supports a SIADH-like pattern over a hypovolemic cause. But don't diagnose SIADH yet: you cannot call SIADH until cortisol and TSH are back and until you have corrected the patient.
Calculate the Na deficit (only for planning): Δ = (target − current) × TBW. TBW for a 60 kg woman ≈ 0.5 × 60 = 30 L. To raise Na by 4 mEq/L: 4 × 30 = 120 mEq of Na needed. 100 mL of 3% NaCl contains 51 mEq → roughly 2 × 100 mL boluses will rise her 4 mEq/L. But do not use the calculation to dose — dose by bolus-and-check.

Stage 3 · Pathophysiology

Why Low Sodium Causes Seizures — The Brain in 100 mL of Water

Before the bolus runs, understand what you are fighting. The seizure is not "low sodium"; it is cerebral edema from osmotic water entry into astrocytes. The math is brutal: in an adult skull with a fixed volume of 1400 mL, as little as 4–8% increase in brain water raises ICP toward herniation.

Click to expand the mechanism ↓

The cellular event: Plasma Na falls → plasma osmolality falls → free water diffuses into neurons and glia along its osmotic gradient (via AQP4 channels concentrated on astrocytic end-feet). Cells swell. In the brain, this happens inside a sealed container.
First-minute defense (volume regulatory decrease): Cells immediately extrude K⁺, Cl⁻, and water through stretch-activated channels (TRPV4, VRAC). This can move 5–10% of cell volume within minutes but is not enough to fully compensate.
Hours-to-days defense: Brain cells export organic osmolytes — myo-inositol, taurine, glutamate, glutamine, creatine, glycerophosphocholine — through SMIT and BGT1 transporters. By 48 h, the brain has largely normalized its volume at the new low tonicity. This is why chronic hyponatremia is symptomatically milder and why correcting it too fast is dangerous.
What acute (<48 h) hyponatremia looks like inside: Adaptation has not had time to happen. Brain water is 5–10% above baseline. ICP rises; cerebral perfusion pressure falls; ischemia → seizure, herniation. Pre-menopausal women (estrogen reduces Na⁺/K⁺-ATPase activity) and children (higher brain:skull ratio) are at highest risk — this is why EAH is disproportionately fatal in young women.
Why rapid correction works (and why it must be small): A 4–6 mEq/L rise raises plasma osmolality by ~8–12 mOsm/kg — enough to pull water out of swollen brain and stop the seizure — but small enough to avoid overshoot into the danger zone of osmotic demyelination (which becomes a risk only if the brain has had time to adapt AND you overshoot).

Clinical-pathology key concept In acute hyponatremia, the enemy is brain edema. In chronic hyponatremia, the enemy is rapid correction of the adapted brain. The same Na number can demand opposite tempos of correction depending on the clock.

Stage 4 · Acute Management

3% NaCl Bolus — The "100 / 100 / 100" Rule

The single best-evidence move in severe symptomatic hyponatremia is bolus (not infusion) hypertonic saline. Sterns and colleagues showed that bolus dosing lets you titrate to symptom resolution while avoiding overshoot that continuous infusions produce.

Click to expand dosing detail ↓

First-line · Severe symptoms

3% NaCl — 100 mL bolus IV over 10 min

Peripheral IV acceptable for the 100 mL bolus (pH 5.0–6.0, osmolarity 1026 mOsm/L; short duration mitigates phlebitis risk). Central access preferred for sustained infusions.

Repeat the 100 mL bolus up to two more times (total three boluses, 300 mL, ≈153 mEq Na) at 10-minute intervals if seizure persists or GCS not improving. Each 100 mL bolus raises serum Na ≈1.5–2 mEq/L in a 60 kg adult.

Why 100 mL works — the arithmetic

3% NaCl = 30 g NaCl / L = 513 mEq Na / L = 51.3 mEq Na per 100 mL

In a 60-kg woman, TBW ≈ 30 L (female coefficient 0.5).

ΔNa ≈ (Na_infusate − Na_serum) / (TBW + V_infusate)
= (513 − 118) / (30 + 0.1) = 395 / 30.1 ≈ +1.3 mEq/L per 100 mL

Three boluses → projected rise ≈ 4 mEq/L → clears the seizure threshold (usually at ≈ +4 mEq/L).

Expert panel 2014 / ERA-EDTA 2014 — agreement For severe symptoms: 150 mL 3% NaCl over 10 min (ERA-EDTA) or 100 mL 3% NaCl over 10 min (US expert panel), repeated up to twice more if symptoms persist. Target a 4–6 mEq/L rise within the first hour — stop bolusing when symptoms resolve or this rise is achieved, whichever comes first.

What NOT to do Do not start a hypertonic saline drip at 1 mL/kg/hr empirically and walk away — this is the classic cause of overcorrection. Do not use normal saline to treat severe symptoms (it is not hypertonic enough to pull water out of the brain quickly). Do not give IV fluid before you have a sodium result if there is any suspicion of hyponatremia and the patient is hemodynamically stable.

Check sodium: Point-of-care / iSTAT Na at 20 min after first bolus, then q2h for first 6 h, then q4h for the remainder of the first 24 h.
Endpoint of bolus phase: Any of: seizure stops, GCS improves by ≥2 points, or Na rises by 4–6 mEq/L. Whichever happens first.
Do not exceed: 6 mEq/L rise in the first 6 hours. 8 mEq/L rise in the first 24 hours (if chronicity unknown — default to chronic).
After bolus phase: Transition to the correction-rate control phase (Stage 5) — often with DDAVP "clamp" if overcorrection risk is high.

Stage 5 · Correction Math

Adrogué–Madias, Bedside — and Why It Is Often Wrong

After the bolus phase ends, you need a plan for the next 24 h. The Adrogué–Madias formula is the most commonly taught tool. It is useful as a starting point, but it systematically under-predicts the Na rise when the ADH drive lifts — and must be paired with frequent re-measurement.

Click to expand the formula and its limits ↓

Adrogué–Madias (single-infusate form)

ΔNa per L infusate = (Na_inf + K_inf − Na_serum) / (TBW + 1)

Infusate menu: 3% NaCl 513 mEq/L · 0.9% NaCl 154 · D5½NS 77 · D5¼NS 34 · D5W 0

TBW = weight (kg) × 0.5 (adult female) or × 0.6 (adult male) or × 0.45 (elderly female)

Worked example: 60-kg woman, post-bolus Na 122, target +4 over next 12 h on 3% NaCl:
ΔNa/L = (513 − 122) / (30 + 1) = 391 / 31 ≈ +12.6 mEq/L per L
To raise 4 mEq/L → 4/12.6 ≈ 0.32 L of 3% saline over 12 h = ≈ 26 mL/hr

Why the formula under-predicts The equation assumes a closed system and ignores ongoing renal water losses. When the cause of hyponatremia resolves (e.g., nausea stops, post-op ADH wanes, hypovolemia is corrected), ADH drops off and the kidney rapidly excretes free water — generating a brisk autocorrection on top of the infusate-driven rise. Classical cases: a hypovolemic hyponatremic patient given saline overcorrects because isotonic saline looks hypertonic relative to their Na of 120 and removing the volume stimulus to ADH lets them dump water.

Rule of thumb — "thirds": In an acute SIADH-pattern patient: 3% NaCl at ~1 mL/kg/hr raises Na by ~1 mEq/L/hr. In a hypovolemic patient receiving NS: expect Na rise + ADH shutoff autocorrection; cut your planned rate by a third or preemptively use DDAVP.
Barsoum–Levine variant: Accounts for urine output and urine [Na + K]. More accurate when ADH is turning off (water-losing phase) but mathematically clunky at the bedside. Reserve for the second-day plan on the renal consult service.
Bottom line: Use Adrogué–Madias to set the initial infusion rate. Then re-measure Na q2h until stable. The formula is a compass, not a GPS — let the measured sodium steer the ship.

Stage 6 · Rate Limits

The 6 / 8 / 10 Mantra and the "Sterns Curve"

Once the emergency is stopped, everything slows down. The correction-rate ceiling is where ODS risk lives. Know the numbers, know who is high-risk, and treat the first 24 hours differently from the second.

Click to expand the rate limits ↓

Goal

4–6

mEq/L rise in the first hour (severe symptoms)

Expert panel 2014

Limit 24 h

≤ 8

mEq/L / 24 h — if ANY high-risk feature

ERA-EDTA 2014

Limit 24 h

≤ 10–12

mEq/L / 24 h — low-risk, chronic

US expert panel

Limit 48 h

≤ 18

mEq/L / 48 h — any patient

All guidelines

High-risk for ODS — treat as ≤ 8 in 24 h (1) Na < 120 mEq/L; (2) chronic alcoholism; (3) malnutrition or liver disease; (4) hypokalemia (K < 3.0); (5) advanced age; (6) hypoxia. Any one of these downgrades the ceiling to 8 mEq/L / 24 h and mandates DDAVP-clamp thinking from the start.

Why the clock starts at the first elevated value: If the Na comes up 4 mEq/L in the first hour (from 118 to 122), the remaining "budget" for the next 23 hours is ≤4 mEq/L. This is the single most commonly missed piece of bookkeeping on rounds. Post the 24-hour Na goal at the head of the bed.
Re-lowering sodium if you overshoot: If Na rises >10 in 24 h OR >18 in 48 h despite best efforts, actively re-lower. Give DDAVP 2 μg IV and D5W 3 mL/kg over 1 hour (repeat as needed) to bring Na back within the safe corridor. This is counter-intuitive but saves brains.
Frequency of monitoring: q1–2 h during the bolus phase; q2–4 h for the rest of the first 24 h; q4–6 h for the second 24 h if trajectory is smooth.
Urine output is your other window: A sudden onset of dilute, high-volume urine (>100 mL/hr clear urine, urine osm <200) tells you ADH has shut off. Expect a rapid Na rise in the next 2–4 hours unless you intervene — this is the moment to give DDAVP.

Stage 7 · DDAVP Clamp

The Counter-Intuitive Move: Give the Thing the Kidney Is Already Over-Using

A water-diuresis overshoot is what kills neurons via ODS. By saturating V2 receptors with exogenous DDAVP (desmopressin), you stop the water diuresis and convert a runaway correction back into one you control with hypertonic saline.

Click to expand the clamp strategy ↓

The two flavors of clamp Proactive: DDAVP 2 μg IV/SC q6–8 h started at the same time as 3% NaCl. Use when overcorrection is likely (hypovolemic cause being corrected with saline; thiazide just stopped; beer drinkers resuming eating). Sood 2013 (n=25) showed this strategy gave a median rise of exactly 6 mEq/L / 24 h with zero cases of overcorrection.

Reactive: DDAVP 2 μg IV given the moment urine output surges (>100 mL/hr) or Na rise exceeds target. Rescues a forming overshoot. Garrahy 2021 found reactive clamp reduces overcorrection but is slightly less reliable than proactive.

Standard DDAVP clamp dose

Desmopressin 2 μg IV/SC q6–8 h

Onset within 15–30 min; duration 6–12 h. Can go peripheral.

While the DDAVP is on board, dose Na deliberately using 3% NaCl at a rate calculated from Adrogué–Madias. This lets you titrate Na by input alone, since the kidney is now a closed door for water. Fluid balance per shift: in < out by <1 L (avoid accumulated overload → pulmonary edema). Plan 24–48 h on clamp; wean as cause resolves.

Indications: (1) Hypovolemic hyponatremia being corrected (SIADH of the correction phase); (2) Thiazide-induced hyponatremia; (3) Beer potomania / tea-and-toast on re-feeding; (4) Post-operative transient SIADH that is now resolving; (5) Any time urine osm starts dropping rapidly mid-correction.
Trap #1 — treating mild polyuria only: Giving DDAVP after Na has already overshot by 10 mEq/L is too late — damage is done. Clamp BEFORE the overshoot, or as soon as it starts.
Trap #2 — losing track of water balance: On DDAVP, the kidney cannot get rid of water. If you run D5W in someone who is clamped, Na will fall rapidly. Conversely, 3% NaCl on a clamped patient will rise Na predictably.
Duration: Plan 24–48 h on clamp. Wean by spacing DDAVP doses once the underlying driver is resolved and Na is >130 with trajectory flat.

Stage 8 · Etiology

Once She's Awake — Finishing the Workup

With Na climbing safely, the job is to explain why. In this runner, three mechanisms likely stacked. In a different patient the same Na might come from a completely different combination. The post-stabilization workup is where the pattern is named.

Click to expand the workup checklist ↓

Repeat history (now that GCS is 14): Exact fluid intake on race day (in her case: 3.2 L of water plus 2 bottles of sports drink over 5 hours). Medications within 30 days (she took sertraline 50 mg qAM and ibuprofen 600 mg 2 hours pre-race). Any nausea during the race (yes, severe — a powerful non-osmotic stimulus to ADH).
TSH: Severe hypothyroidism (myxedema) can cause hyponatremia via reduced cardiac output → non-osmotic ADH. A mildly elevated TSH (4–10) does NOT cause hyponatremia — do not anchor on a borderline TSH.
Random cortisol: A random cortisol <5 μg/dL is suspicious for adrenal insufficiency; >18 excludes. Intermediate values require a cosyntropin stimulation test. Glucocorticoid deficiency causes hyponatremia by failure to suppress CRH → non-osmotic ADH plus reduced free water excretion.
Volume status: In retrospect she was euvolemic to mildly hypervolemic (water-loaded). Skin turgor normal, no orthostasis, JVP 6 cm, no edema. BUN 8 (low — dilutional), UA 3.1 (low — suppressed RAAS from water loading), FeNa 1.1%.
Pattern name: Exercise-associated hyponatremia (EAH) — a variant of SIADH physiology triggered by non-osmotic ADH release (pain, nausea, heat, exercise) layered on voluntary polydipsia, often potentiated by SSRIs and NSAIDs.

Why she was uniquely vulnerable (1) Pre-menopausal female → estrogen reduces Na⁺/K⁺-ATPase activity, impairing volume regulatory decrease in neurons; (2) SSRI → SIADH; (3) NSAID → blocks renal prostaglandins that normally dilute urine; (4) Nausea → non-osmotic ADH; (5) Endurance exercise → another non-osmotic stimulus; (6) Aggressive water drinking per "hydration" messaging. This is the classic EAH stack.

Stage 9 · Definitive Treatment

Off the Drip — Building a Safe Discharge Plan

By 36 hours, her Na is 133, GCS 15, ambulating with PT. The job now is to identify and remove the drivers and teach her how to avoid a repeat — EAH recurrence rates are >30% in runners who race again without changing behavior.

Click to expand the discharge plan ↓

Medication review: Sertraline — switch to a non-SSRI if mood treatment needed (bupropion, mirtazapine do NOT cause SIADH). If SSRI continued, counsel on water intake limits. NSAID — avoid pre- and peri-race.
Hydration plan for future racing: Drink to thirst only. Do not "hydrate ahead." Target urine that stays pale yellow (not colorless). Endurance sports medicine guidance: weigh in and out; do not gain weight over the race. Practice fluid intake protocols during training, not for the first time on race day.
Education: Teach symptoms of early hyponatremia (headache, nausea, puffy fingers, confusion) and to stop drinking and seek help if they appear. Provide the patient and her running partner a one-page handout.
Follow-up: BMP at 1 week (should be normal on ad-lib water), repeat at 1 month. Referral to sports medicine for a race-day hydration plan.
Red-flag teach-back before discharge: "If you ever feel confused, headachy, or nauseous and you've been drinking a lot of water, stop drinking and go to the ED. Hyponatremia kills brain tissue faster than dehydration kills kidneys." Have her repeat it back.

Stage 10 · Prognosis

What the Literature Says Happens Next

Severe acute symptomatic hyponatremia carries a mortality of 10–20% historically, driven mostly by brain herniation in the first 24 hours. With rapid recognition and bolus hypertonic saline, survival to neurologically intact discharge is now >95% in athletes.

Click to expand outcomes data ↓

In-hospital mortality: Acute symptomatic hyponatremia (Na ≤120 with severe symptoms): 10–20% in the pre-hypertonic-saline era (Arieff 1986). Contemporary series with bolus 3% NaCl: 1–5%.
Neurological recovery: >90% of athletes with EAH who receive bolus hypertonic saline return to baseline neurological function. Delayed recognition (any delay >4 hours after seizure) increases risk of permanent deficit to 10–20%.
ODS risk in this patient: Very low — because acute hyponatremia does not allow time for brain osmolyte export, ODS requires an adapted brain. A Na <120 for <48 h that is corrected at any speed rarely causes ODS.
Recurrence: >30% in runners who race again without changing behavior. Halved with pre-race education + no NSAIDs + drinking to thirst.
Long-term Na handling: Normal — EAH does not cause residual nephrogenic defects. Once the triggering combination is removed, sodium regulation returns to baseline.

Stage 1 · Presentation

The Insidious Decliner — Weeks of Malaise, Falls, and "Just Not Right"

A 72-year-old man with stage IIIA small-cell lung cancer is admitted after a mechanical fall at home. His daughter reports six weeks of progressive fatigue, word-finding difficulty, and two unwitnessed falls. On admission BMP he is Na 118 — but he is awake, oriented, and conversational. This is chronic hyponatremia. It looks nothing like the runner in Journey 1.

Click to expand the clinical vignette ↓

Why this patient walks in at Na 118 Over weeks, the brain has exported organic osmolytes (myo-inositol, taurine, glutamate, glycine, creatine) and achieved near-normal cellular volume at the new low tonicity. Cerebral edema is minimal, so overt symptoms (seizure, coma) are absent. But the adaptation is incomplete: sub-clinical attentional defects, gait instability, and osteoporosis emerge. Every 1 mEq/L below 140 increases fall risk (Renneboog 2006), and chronic hyponatremia doubles fracture risk at any given bone density (Kinsella 2010).

Admission history: Six-week-old SCLC diagnosis; one cycle of carboplatin/etoposide 2 weeks ago. Medications: ondansetron PRN, dexamethasone 4 mg during chemo only (none in the last 7 days), omeprazole, atorvastatin. No diuretics, no SSRI, no recreational drugs.
Examination: BP 128/76 supine / 124/72 standing (no orthostatic drop), HR 78 → 84 on standing, weight 68 kg (stable per family). Mucous membranes moist. No edema. JVP 6 cm. No crackles. Abdomen soft. Mental status: alert, oriented ×3, subtle word-finding hesitancy, impaired serial 7s.
Prior labs: Na 134 one year ago (PCP baseline) → 128 two months ago (oncology intake) → 118 today. A six-month drift. This trajectory by itself is diagnostic of chronic hyponatremia.
Volume status verdict: Clinically euvolemic — no orthostasis, no edema, no mucous membrane dryness, no weight change, no recent diuretic or GI loss. Euvolemic hyponatremia in an adult with a new cancer is SIADH until proven otherwise.
Why the falls matter: Two prospective studies (Renneboog, Gankam Kengne) show that chronic Na 124–132 causes measurable attentional and gait deficits that resolve with correction. In this man, the falls are probably his sodium, not his age — and correcting him is likely to change his 6-month functional trajectory.

Stage 2 · Workup

The Bartter–Schwartz Checklist — Essential Criteria and Supportive Features

SIADH is a diagnosis of exclusion. Before you commit, walk the full checklist. Miss an adrenal insufficiency or a hypothyroidism and the patient will not respond to fluid restriction.

Click to expand the criteria ↓

Key labs — hospital day 1

Na118 mEq/L

K4.1

Cr0.8 mg/dL

BUN6 mg/dL

UA2.6 mg/dL

Glucose94

Serum osm248 mOsm/kg

Urine osm528 mOsm/kg

Urine Na72 mEq/L

TSH · free T41.8 / 1.2 (normal)

Random cortisol 080016.4 μg/dL

Copeptin (if available)18 pmol/L

Bartter–Schwartz essential criteria — all required 1. Hypotonic hyponatremia: Na <135 AND serum osm <275 mOsm/kg.
2. Urine osm >100 mOsm/kg in the face of hypotonicity (ADH inappropriately active).
3. Clinically euvolemic (no orthostasis, no edema, no dehydration signs).
4. Urine Na >30 mEq/L on a normal salt intake (rules out effective-volume depletion).
5. Normal thyroid function (TSH in range).
6. Normal adrenal function (random cortisol >18, or stim test if borderline).
7. No recent diuretic use (thiazides within 2 weeks — including stealth doses in combination pills).

Supportive features Low BUN (<10) and low uric acid (<4) — both are "washed out" by the mild volume expansion of chronic water retention. Normal renal function. Prompt response (>5 mEq/L rise in Na) to a trial of fluid restriction. Hyponatremia that worsens after saline infusion (the classic "reverse" result).

Copeptin — if you have it: Copeptin is the C-terminal fragment of pre-pro-ADH, secreted equimolar with ADH but stable in plasma (ADH itself has a half-life of minutes). Copeptin >2.6 pmol/L with low plasma osm = inappropriate ADH activity. Copeptin >20 in a dehydrated patient = hypovolemia (appropriate ADH). Refardt 2018 used copeptin to differentiate etiologies in the ambulatory workup.
The saline-infusion test (rarely needed): In diagnostic equipoise, 2 L NS over 24–48 h. SIADH: Na falls or stays the same (all Na excreted in concentrated urine + free water retained). Hypovolemia: Na rises within 6 hours as volume repletes and ADH shuts off. Don't do this routinely — it can worsen SIADH.
Imaging / evaluation for cause: In this patient the cause is already known (SCLC — the prototype ectopic-ADH tumor). In patients without a known driver: CT chest (small-cell and non-small-cell lung), MRI brain (pituitary, hypothalamus), full medication review (SSRIs, SNRIs, carbamazepine, oxcarbazepine, vincristine, cyclophosphamide, MDMA).

Stage 3 · Pathophysiology

The V2 Receptor in a Cancer That Makes Its Own Vasopressin

SCLC cells derive from neuroendocrine precursors and can ectopically transcribe the AVP gene, releasing functional arginine vasopressin that binds renal V2 receptors. The pituitary is normal; the kidney is normal; the tumor is the endocrine organ.

Click to expand the molecular mechanism ↓

ADH synthesis in SIADH: Normally, ADH is made in magnocellular neurons of the supraoptic and paraventricular nuclei, stored in the posterior pituitary, and released in response to osmotic (even a 1 mOsm rise above set-point) or non-osmotic (volume, nausea, pain) triggers. In SIADH, ADH release is inappropriate to the osmotic state (plasma is already hypotonic). In ectopic SIADH, the source is tumor, not pituitary.
V2 receptor signaling: ADH binds V2 (Gs-coupled) on the basolateral principal cell membrane → adenylyl cyclase → cAMP → PKA → phosphorylation of serine-256 on AQP2 → AQP2 vesicles fuse with the apical membrane → water channels open → free water moves down its gradient from dilute tubular fluid into the hypertonic medullary interstitium and then into the blood.
Why Na falls (not total body sodium): Total body Na is roughly normal in SIADH — maybe slightly elevated. What changes is free water retention. Volume expansion suppresses aldosterone and activates atrial natriuretic peptide, so the kidney starts excreting Na into the urine (that's the urine Na >30 mEq/L) — this maintains a near-steady-state volume but at a lower Na concentration. This is the "reset osmostat" variant when the ADH set-point is low but functional.
Four classic SIADH patterns (Robertson / Zerbe): Type A (30%): erratic, unregulated ADH release — classic of small-cell lung cancer.
Type B (30%): chronic leak — steady low-level ADH release that fails to suppress.
Type C (~35%, "reset osmostat"): ADH release regulated by osmolality but at a lower set-point — Na stable around 125–130; fluid restriction does not help much.
Type D (<5%): normal ADH — inappropriate AQP2 gain-of-function or nephrogenic syndrome of inappropriate antidiuresis (NSIAD) from V2 receptor mutations.
Drug-induced SIADH mechanisms: SSRIs: facilitate serotonin-induced ADH release (highest risk in elderly women within first 2 weeks). Carbamazepine/oxcarbazepine: direct V2 agonism (oxcarbazepine >10× risk of carbamazepine). Vincristine/cyclophosphamide: tubular toxicity + direct ADH release. MDMA ("ecstasy"): stimulates ADH + causes polydipsia. Thiazides: separate mechanism (see Journey 3).

Stage 4 · First-line Treatment

Fluid Restriction + Salt Tablets — What Actually Works

In a euvolemic, stable SIADH patient without severe symptoms, first-line therapy is water restriction. The single best predictor of whether it will work is the Furst ratio.

Click to expand the evidence ↓

The Furst Ratio — will fluid restriction work?

Furst ratio = (Urine Na + Urine K) / Serum Na

Worked: (72 + 28) / 118 = 100 / 118 = 0.85

< 0.5 → fluid restriction works (kidney is generating free-water clearance)

0.5–1.0 → fluid restriction may work, but restriction must be aggressive (<800 mL/day)

> 1.0 → fluid restriction alone will fail; the kidney is making urine more concentrated than plasma — need salt tablets, loop diuretic, urea, or tolvaptan

First-line regimen

Fluid restriction to 800–1000 mL/day + Salt tablets 2 g PO TID + Furosemide 20 mg PO daily

Fluid restriction includes all intake (water, coffee, soup, fruit, IV meds). Patients routinely violate restriction without realizing — teach the "no hidden water" rule.

Furosemide uncouples the medullary gradient, preventing the kidney from concentrating urine maximally. This blunts SIADH physiology even when ADH is still "on." Salt tablets replace the Na the kidney dumps. Monitor K+ (may drop with loop).

Why fluid restriction fails in ~40% of SIADH (1) Non-adherence (underestimated drinking); (2) tight Furst ratio >1.0 (concentrated urine outpaces restricted intake); (3) "reset osmostat" type where the patient defends a Na of 128 and fluid restriction doesn't budge it. In these patients, escalate — do not just keep tightening the restriction.

Oral urea — 2nd-line, under-used: 15–30 g PO daily (mixed in orange juice to mask taste). Induces osmotic diuresis, increasing free-water excretion even when ADH is high. Decaux 2001, Verbalis 2020: effective, cheap, doesn't cause overcorrection, safe long-term. Side effect: GI upset. Under-prescribed in the US because of taste; European uptake is higher.
Tolvaptan — 3rd-line, hospital-only in US: Selective V2 receptor antagonist. SALT-1 and SALT-2 (Schrier 2006) showed 4–6 mEq/L rise within 4 days. US label: initiate in hospital, do not use >30 days (hepatotoxicity, SALTWATER extension). Starting dose 15 mg PO daily, up-titrate to 30–60 mg as tolerated. No fluid restriction during tolvaptan (patient will be thirsty and drink).
Endpoint of treatment: Target Na 130–135. Correcting past 135 in a chronic SIADH patient adds little benefit and increases overcorrection risk. "Good enough" sodium is better than "perfect" sodium.
Why not just use hypertonic saline?: In a chronic euvolemic SIADH patient without severe symptoms, 3% NaCl is overkill and carries overcorrection risk. Reserve hypertonic saline for severe symptoms or when Na must be raised faster than dietary measures allow.

Stage 5 · Vaptans

SALT-1 / SALT-2 / EVEREST — Where Tolvaptan Fits

Vaptans transformed SIADH pharmacology on paper; in practice, cost, hepatotoxicity, and the US 30-day hospital-only label keep them in a small niche. Understand the evidence so you know when to reach for them.

Click to expand the trial data ↓

SALT-1 and SALT-2 (Schrier 2006, NEJM): n = 448 combined. Hyponatremic patients with SIADH, HF, or cirrhosis randomized to tolvaptan vs placebo, 30-day follow-up. Tolvaptan raised serum Na by 4.4 mEq/L at day 4 and 5.6 mEq/L at day 30 vs placebo (+0.3 and +1.8). Symptom improvement by day 30. No overcorrection if monitored.
EVEREST (Konstam 2007, JAMA): n = 4133 hospitalized with worsening HF. Tolvaptan vs placebo added to standard care. No difference in mortality or HF morbidity at long-term follow-up despite improvements in body weight, dyspnea, and serum Na. Tolvaptan corrects the number but does not change outcomes in HF. Led to HF-hyponatremia vaptan de-emphasis.
SALTWATER (Berl 2010): Open-label extension of SALT trials. Tolvaptan sustained Na improvement out to 4 years. But this era pre-dated the hepatotoxicity label.
TEMPO 3:4 and hepatotoxicity (Torres 2012): Tolvaptan slowed ADPKD progression but caused dose-dependent ALT/AST elevations in ~5% and idiosyncratic hepatotoxicity in 3 of 1445 patients. FDA 2013 black-box warning → US label now restricts use to ≤30 days for hyponatremia and requires hospital initiation.
Who is the right patient for tolvaptan?: Moderate-to-severe chronic SIADH in hospital, Na 120–130, who has failed fluid restriction, has Furst ratio >1.0, and in whom normalizing Na will allow discharge to SNF or home. Also: symptomatic euvolemic/hypervolemic hyponatremia in HF when Na < 125 and diuresis is failing — but expect no mortality benefit.

Tolvaptan cautions Black-box: hepatotoxicity — monitor LFTs baseline, weekly × 18 months if continued beyond the hyponatremia course. Do not use in hypovolemic patients (will worsen). Do not use in anuric patients (kidney has to make urine for a V2 antagonist to work). Risk of very rapid Na rise in the first 24 h — start in hospital, no fluid restriction (let the patient drink freely), recheck Na at 8 and 16 h.

Stage 6 · Etiologic Subtyping

Find and Remove the Trigger — or Live with It

SIADH has a differential. Anchoring on the most obvious cause misses the 10–20% of patients with a second driver that is the real problem.

Click to expand the systematic search ↓

Malignancy-related (ectopic ADH): Small-cell lung cancer (30–40% of SIADH), extrapulmonary small-cell, head & neck SCC, duodenal/pancreatic tumors, lymphoma (rarely). Treat the cancer → SIADH resolves or becomes manageable with restriction.
Pulmonary (non-malignant): Pneumonia (especially Legionella), TB, aspergillosis, acute respiratory failure, positive-pressure ventilation. Mechanism: hypoxic hypothalamic stimulation + thoracic pressure changes affecting baroreceptors.
CNS: Subarachnoid hemorrhage (classic — differentiate from CSW), meningitis, encephalitis, stroke, head trauma, Guillain-Barré, tumors. Mechanism: direct hypothalamic/pituitary irritation.
Medications: SSRIs (sertraline, citalopram ≫ fluoxetine), SNRIs (venlafaxine), carbamazepine, oxcarbazepine (10× carbamazepine risk), valproate, vincristine, cyclophosphamide (especially IV), ifosfamide, MDMA, opiates, amiodarone, haloperidol, clofibrate. Thiazides are a separate mechanism, not classic SIADH.
Hormonal: Glucocorticoid deficiency (secondary adrenal insufficiency — rule out before diagnosing SIADH). Severe hypothyroidism. Nausea (any cause) is itself a powerful non-osmotic ADH trigger.
Post-surgical: Peaks day 1–3. Driven by pain, nausea, opioids, and hypotonic IV fluids. A perfectly preventable complication — use isotonic fluids perioperatively, check Na day 2 in anyone with prolonged nausea.
Idiopathic / "reset osmostat": When workup is clean and Na is stably 125–132. Often elderly, often with osteoporosis and falls. Manage expectations: cure is unlikely; the job is to keep Na >125 and reduce falls.

Cerebral salt wasting (CSW) — the SIADH look-alike After SAH, TBI, or intracranial surgery: hyponatremia + high urine Na + volume depletion (not euvolemia). Mechanism involves BNP elevation driving natriuresis. Treatment: salt and saline (opposite of SIADH). Distinguishing requires careful volume status and urine output assessment. Fludrocortisone 0.1–0.3 mg/day is sometimes used. This is a frequent boards question and a real trap in neuro-ICUs.

Stage 7 · Monitoring

Hospital Monitoring — What to Recheck and When

Chronic SIADH rarely requires the q2h sodium vigil of severe acute hyponatremia, but patients overcorrect on fluid restriction alone when the underlying driver resolves (e.g., post-op day 4, SSRI cleared, pneumonia treated).

Click to expand the monitoring plan ↓

Baseline Na 118, fluid restriction + salt tabs: Check Na at 12 and 24 h. If rising >6–8 mEq/L in 24 h, loosen restriction or add DDAVP 1–2 μg SC × 1 to slow correction.
On tolvaptan: Na at 4, 8, 16, 24 h. Stop tolvaptan if rise >8 mEq/L in 24 h; give D5W to re-lower if overshoot. Daily LFTs through day 7.
Daily — all chronic SIADH: Na, BUN, Cr, K, urine osm, urine Na, strict I/O, daily weights. Document symptom progression (ask about headache, nausea, mental fog, gait).
Discharge criteria: Na >125 stable for 24 h, able to maintain fluid restriction (teach-back confirmed), follow-up labs at 1 week arranged, underlying cause addressed or plan in place.
Outpatient follow-up: BMP weekly × 2 then q2–4 weeks while tuning restriction or titrating urea/tolvaptan. DXA if first SIADH episode — chronic hyponatremia is a fracture risk factor.

Stage 8 · Prognosis

Chronic SIADH and Long-Term Outcomes

Chronic hyponatremia is not benign. In SCLC specifically, Na is an independent marker of burden and prognosis. In older adults broadly, correcting chronic hyponatremia reduces falls and hospitalizations.

Click to expand outcomes evidence ↓

SCLC + SIADH — prognosis: Paraneoplastic SIADH at diagnosis is associated with more advanced disease and shorter median survival, but resolves in ~60–80% after effective chemotherapy — Na often doubles as a biomarker of response.
Fall and fracture risk: Chronic Na 125–135 roughly doubles fall risk (Renneboog 2006, Ayus 2011) independent of age and comorbidity. Two prospective studies show normalizing Na improves gait and attention — but no RCT has shown reduced fracture rate.
Mortality in hospital: In-hospital mortality climbs roughly linearly: Na 130–134 ~1.4× baseline; 125–129 ~1.6×; 120–124 ~2×; <120 ~3–5× (Wald 2010, Waikar 2009). Whether this is causal or a marker of illness severity remains debated; some correction benefit is shown in observational data.
Reversibility of cognitive and gait findings: Gankam Kengne 2010, Renneboog 2006: correcting Na from ~125 to >135 measurably improved balance, attention, and reaction time. Whether this translates to long-term outcomes has not been definitively shown in RCT.

Stage 1 · Presentation

The Elderly Woman with "UTI Symptoms" — Recognising a Classic

An 81-year-old woman is referred from assisted living for "altered mental status and dehydration." She is on HCTZ 25 mg daily (started 9 days ago for BP creeping to 152/84), lisinopril 10 mg, atorvastatin, and vitamin D. Admission Na is 119. She has a fresh facial bruise from a fall two days ago that "nobody mentioned" at triage.

Click to expand the clinical pattern ↓

The demographic: who gets thiazide-induced hyponatremia Thin, elderly, female, on a low-potassium diet, within 2 weeks of starting or dose-increasing a thiazide. This is not a subtle phenotype — the population-attributable risk of thiazide in hospitalized hyponatremia in people >75 is >20%. Chlorthalidone > HCTZ at equivalent BP-lowering doses (longer half-life, more water retention). Indapamide also high-risk. Combination pills hide thiazide in plain sight (lisinopril/HCTZ, losartan/HCTZ, triamterene/HCTZ).

Key features on arrival: BP 118/68 lying, 102/62 standing (orthostatic drop), HR 74 → 92. Weight down 1.5 kg from AL baseline 2 weeks ago. Mucous membranes mildly dry. No edema. JVP 4 cm. Confused, oriented to person only.
Lab surprises: Na 119, K 3.1 (low!), Cl 81, HCO₃ 28 (metabolic alkalosis from thiazide), Mg 1.4, Cr 1.1 (up from 0.8 baseline), BUN 28 (up from 14), UA 3.8. Urine Na 54, urine osm 480, urine K 32.
Why this looks like SIADH but isn't: Urine Na >30 and urine osm >100 check two SIADH boxes — but the urine Na is elevated because thiazide directly inhibits DCT Na reabsorption. Volume status is ambiguous (contraction is subtle) and BUN is up. The trick is to recognise: a patient on thiazide with hyponatremia is NOT SIADH — it's thiazide-induced hyponatremia until proven otherwise, which may have a component of mild hypovolemia, ADH activation, and impaired urinary dilution.
Recent behavior: Family reports she has been drinking more water "because she read blood pressure meds make you dehydrated" and snacking on toast and tea — a low-solute diet that compounds the inability to excrete free water.

Stage 2 · Pathophysiology

Three Mechanisms Stacked: Why Thiazides Do This

Thiazide-induced hyponatremia is not one thing — it is a compound mechanism that explains both the speed of onset and the risk of overcorrection on cessation.

Click to expand the mechanism ↓

Mechanism #1 — Impaired dilution: The DCT is the nephron's cortical diluting segment. Normally, thick ascending limb pulls out NaCl without water, then the DCT pulls out more NaCl (via NCC, the Na-Cl cotransporter), dropping urine osm to as low as 50 mOsm/kg. Thiazides block NCC → the DCT cannot subtract any more solute → urine stays at 150–200 mOsm/kg minimum. Add any water load and the kidney cannot dilute fast enough → serum Na falls.
Mechanism #2 — Non-osmotic ADH: The diuretic effect itself causes ~1 L of volume loss over the first 3–7 days. If water intake exceeds urinary losses, plasma dilutes; the baroreceptor-mediated non-osmotic ADH release continues because the body senses (and defends) volume, not Na. So ADH stays "on" even as Na falls.
Mechanism #3 — Genetic susceptibility: Thiazide-induced hyponatremia tracks strongly in families (siblings and first-degree relatives of index cases). Ware 2017 identified a SNP in the prostaglandin transporter gene SLCO2A1 that is over-represented in thiazide-hyponatremia patients. The functional phenotype appears to be exaggerated AQP2 trafficking when the patient takes a thiazide — not everyone gets this.
Why chlorthalidone > HCTZ: Chlorthalidone half-life is 40–60 h (vs HCTZ 6–15 h). Daily dosing → steady accumulation → steady NCC block. Chlorthalidone is the thiazide in SPRINT, ALLHAT, and most BP trials — and it is the thiazide most often reported in hyponatremia case series. Prefer HCTZ (or ACEI/ARB monotherapy) in patients at risk.
Why hypokalemia matters here: Thiazides cause K wasting directly (increased distal flow → ROMK-mediated K secretion). Hypokalemia is independently associated with worsening hyponatremia (Na⁺/K⁺ ATPase impairment) AND increases ODS risk on correction. Always measure and replete K.

Stage 3 · Initial Workup

Volume Status in Thiazide Hyponatremia — The Great Grey Zone

Thiazide patients are not clearly hypovolemic and not clearly SIADH-pattern euvolemic. The classic teaching distinguishes by urine Na and volume exam — but with a thiazide on board, both are distorted.

Click to expand the assessment ↓

Parameter

Classic SIADH

Thiazide-induced

Volume status

Euvolemic

Mildly hypovolemic or ambiguous

Urine Na

>30 (high)

>30 (falsely high due to thiazide)

Urine osm

>100, often >300

Usually 150–400

BUN

Low (<10)

Often elevated (contraction)

Uric acid

Low (<4)

Often normal or high

Normal

Often low

HCO₃

Normal

High (metabolic alkalosis)

Response to IV NS

Na worsens or no change

Na rises (often rapidly — risk of overcorrection)

The overcorrection trap When you stop the thiazide and let the kidney dilute normally again, ADH drive drops, urine output surges, and Na rises — fast. Classic cases have overshot by 15 mEq/L in 12 hours after a single dose of normal saline. Treat thiazide-induced hyponatremia as high-risk for overcorrection from the start — plan DDAVP clamp or plan gentle restoration with D5W as needed.

Labs to send: BMP with Mg, phosphorus, osm. TSH, random cortisol (rule out adjacent disease — elderly women with falls sometimes have occult adrenal insufficiency). Urine Na, K, osm. Consider copeptin if confusion about mechanism persists.
Medication reconciliation: Check for hidden thiazide in combination pills. Check for SSRIs, PPIs (associated with hyponatremia in elderly), NSAIDs, opioids. Remove what you can remove.
Fall workup: Head CT (she hit her face 2 days ago). Orthostatic vitals. Gait assessment when mental status allows. PT/OT consult.

Stage 4 · Treatment

Stop the Thiazide + Gentle Replete — With a DDAVP Safety Net

She is symptomatic (confusion, falls) but not severely symptomatic (no seizure, no coma). The job is to raise Na safely, at ≤8 mEq/L per 24 h, while anticipating the autocorrection overshoot when the thiazide wears off.

Click to expand the plan ↓

First 6 hours

Hold thiazide · KCl 40 mEq IV · Mg 2 g IV · NS at 75 mL/hr

Correct K first — hypokalemia alone raises ODS risk. Give isotonic saline cautiously; she is mildly contracted so the first 500 mL helps volume, but expect the ADH drive to fall with volume expansion.

Recheck Na at 2, 4, and 6 hours. Target rise 4–6 mEq/L in 24 h (go-slow on an elderly hypokalemic patient — she is high-risk for ODS).

Anticipate the autocorrection at 12–24 h Once the thiazide is washed out (and her volume is repleted), the kidney will dilute urine aggressively. Expect urine osm to drop <100 and urine volume to rise >150 mL/hr. When this starts, give DDAVP 2 μg IV and start D5W at a calculated rate to hold Na in the safe corridor. The exact moment to clamp is when a cumulative 6 mEq/L rise has been achieved OR urine output has surged — whichever comes first.

The "replete K first" rule: Hypokalemia impairs Na⁺/K⁺-ATPase activity in brain cells. Replete K to >3.5 before aggressive Na correction. K replacement itself raises serum Na (via shift of K into cells coupled to Na export). Count K as part of your Na-raising input (use the Adrogué–Madias formula with K included).
Why not 3% saline?: She is not severely symptomatic. Using 3% in this setting is higher-risk because the kidney is primed to autocorrect. Reserve 3% for seizure / coma; use isotonic + thiazide removal otherwise.
Monitor-and-adjust rhythm: Na q2h for the first 12 h, then q4h. I/O q4h. Urine osm q4h (cheap, guides timing of clamp). If rise exceeds 1 mEq/L/hr for two consecutive readings, pre-empt with DDAVP.
When she turns the corner: Expect Na to stabilize at 128–132 within 48–72 h after thiazide withdrawal. Continue mild fluid restriction (1500 mL/day) for a week. Full normalization by day 5–10 is typical.

Stage 5 · Don't Restart

The "Never Again" Rule and the BP Plan

Thiazide-induced hyponatremia will recur on rechallenge. The population attributable risk on re-exposure is >50% within 30 days. Do not restart — ever.

Click to expand the discharge plan ↓

Banned in this patient: Hydrochlorothiazide, chlorthalidone, indapamide, metolazone, any combination pill containing thiazide. Document in the problem list as a formal allergy/adverse reaction.
BP management going forward: Continue lisinopril 10 mg (and titrate to 20 mg) or switch to ARB. Add amlodipine 2.5–5 mg if additional BP lowering needed. If still uncontrolled, consider low-dose spironolactone (watch K). Avoid loop diuretic for pure BP indication in this phenotype.
Patient education: "Your body reacted to a common blood pressure pill. It can happen again if we give you that same pill — even a lower dose or a sister drug. If any new doctor ever tries to start a 'water pill' for BP, stop and call us first."
Family / caregiver communication: Copy the AL nurse on the discharge summary flagging thiazide as contraindicated. Put a wallet card in her purse.
Follow-up: BMP at 72 h post-discharge, 1 week, 2 weeks. PCP visit within 2 weeks. DXA at 3 months (chronic hyponatremia is a fracture risk).

Stage 6 · Outcomes

What Usually Happens to These Patients

With thiazide removal and careful support, >95% of patients return to baseline Na within 2 weeks. ODS is rare when the ≤8 mEq/L / 24 h rule is respected. The real long-term issues are falls, osteoporosis, and recurrence if a clinician misses the history.

Click to expand outcomes ↓

Na trajectory: Typical: 119 → 124 at 24 h → 128 at 48 h → 132 at 72 h → 136 at day 7. The second-day rise often feels alarming — this is the ADH-washout phase and is when DDAVP saves brains.
ODS incidence: Thiazide-induced hyponatremia corrected at rates of 10–12 mEq/L/24 h has a small but definite ODS risk (case series 1–5%). At ≤8 mEq/L/24 h with K replete, ODS is rare (<1%).
Recurrence on rechallenge: >50% within 30 days of restarting a thiazide — regardless of dose. Document as a hard stop in the EHR.
Functional outcomes: If falls and confusion were driven primarily by Na, they resolve within 1–2 weeks of restoration. If the patient also has early dementia, baseline gait disturbance, or osteoarthritis, expect partial improvement only.

Stage 1 · Presentation

The Cirrhotic with Ascites and Na 121 — Hypervolemic but Water-Hungry

A 58-year-old man with NASH cirrhosis (Child–Pugh C, MELD 22) is admitted for worsening ascites and hepatic encephalopathy grade 2. His Na has drifted from 132 two months ago to 121 today. He is on furosemide 80 mg and spironolactone 200 mg daily, with maximum-dose dietary Na restriction. His total body sodium is huge; his effective circulating volume is tiny.

Click to expand the physiology of "empty-tank on a wet body" ↓

The paradox of hypervolemic hyponatremia In cirrhosis and advanced HF, the patient is total-body overloaded (ascites, edema, third-spacing) but effectively underfilled — splanchnic vasodilation (cirrhosis) or low cardiac output (HF) reduces arterial filling, sensed by baroreceptors as volume depletion. This triggers non-osmotic ADH release, RAAS activation, and sympathetic drive. Na AND water are retained, but water more than Na → dilutional hyponatremia.

Exam: BP 98/62, HR 94, afebrile. Obvious ascites (+3), 2+ LE edema to the knees, spider angiomas, palmar erythema, mild asterixis. No JVD (splanchnic pooling). Mucous membranes moist. Weight +4 kg over 2 weeks despite diuretics.
Labs: Na 121, K 3.4, Cr 1.6 (up from 1.1), BUN 38, Bili 4.8, AST 88, ALT 41, INR 1.9, Plt 71, albumin 2.4. Urine Na 8 (very low — intense avidity), urine osm 410, urine K 22. Ascitic fluid: SAAG 1.6, protein 0.9, WBC 140 (PMN 35 — not SBP).
Why urine Na is <10: RAAS is maximally activated; the kidney is avidly reabsorbing Na. This is a defining feature of cirrhotic hyponatremia and distinguishes it from SIADH (where urine Na is >30). It also predicts poor response to dietary Na restriction alone — the kidney is already hoarding.
Why Cr is rising: Pre-hepatorenal syndrome. Reduced effective circulating volume → reduced renal perfusion → reduced GFR. In severe cirrhosis, this can progress to HRS-AKI (formerly HRS-1) with Cr doubling in days. Any diuretic push in this setting is walking the edge.
Why ADH is elevated: Splanchnic and systemic vasodilation (driven by NO from bacterial translocation, TNF, and other mediators) → reduced arterial filling → baroreceptor-driven ADH release despite hypoosmolar plasma. This is the "appropriate-in-a-physiologic-sense, inappropriate-for-Na-handling" ADH pattern.

Stage 2 · Pathophysiology

Splanchnic Vasodilation → RAAS → ADH → Dilutional Na

The cirrhotic hyponatremia cascade is the canonical example of neurohormonal maladaptation. Understanding it explains both why the patient is sick and why every usual therapy has caveats.

Click to expand the cascade ↓

HF version of the same cascade: Reduced cardiac output (HFrEF) → reduced arterial filling → same triad (ADH + RAAS + SNS) → Na and water retention. Hyponatremia in HFrEF is an independent predictor of mortality (Gheorghiade 2007). Every 1 mEq/L below 140 adds risk. ARNI and SGLT2 inhibitors modestly improve Na by reducing neurohormonal drive.
Why urine osm is high: Maximum ADH activity + avid distal water reabsorption → urine osm can reach 600–900 mOsm/kg. With urine Na low (<10) but urine osm high, this pattern distinguishes hypervolemic hyponatremia from other causes.
Albumin's role in cirrhosis: Low serum albumin reduces plasma oncotic pressure, worsening transudation into peritoneal space. IV albumin in selected cirrhotic indications (large-volume paracentesis, SBP, HRS-AKI) expands effective circulating volume and can transiently raise Na by suppressing ADH. It does not cure the underlying problem.

Stage 3 · First-line

Fluid Restriction + Treating the Underlying Disease

In hypervolemic hyponatremia without severe symptoms, the backbone of therapy is fluid restriction to <1 L/day plus treatment of the underlying condition. The Na does not need to be normalized — it needs to be safe.

Click to expand the regimen ↓

Backbone of care — cirrhotic hyponatremia

Fluid restriction <1000 mL/day · continue spironolactone + furosemide at ~100:40 ratio · Na restriction <2 g/day

Spironolactone-predominant because of RAAS activation. Add or increase furosemide if weight loss <0.5 kg/day without ascites or <1 kg/day with ascites.

Stop diuretics if: Na <120, Cr rises >50% from baseline, HE worsens, symptomatic hypotension. Consider IV albumin 25% 50 g if Na <125 and Cr rising (particularly in the setting of large-volume paracentesis >5 L).

AASLD 2021 · Cirrhotic hyponatremia Na 125–135 (mild): fluid restriction alone, continue diuretics cautiously. Na <125: stop diuretics, restrict fluids to 500–1000 mL/day, consider IV albumin. Vaptans are NOT recommended as first-line in cirrhosis — concern for hepatic toxicity. Reserve tolvaptan for symptomatic Na <120 after failure of standard measures, in hospital, <30 days.

Treat the cause, not just the number: Cirrhosis: TIPS if recurrent refractory ascites in appropriate candidates (reduces ADH drive by improving arterial filling via portosystemic shunt), liver transplant evaluation if MELD ≥15. HF: optimize GDMT (ARNI, SGLT2i, beta-blocker, MRA), consider CRT or LVAD if appropriate. The Na often corrects in parallel with these disease-modifying interventions.
TIPS and sodium: Transjugular intrahepatic portosystemic shunt reduces portal pressure, improves arterial filling, and often raises Na by several mEq/L within weeks. But TIPS worsens hepatic encephalopathy in 25–35% and has procedural risks — careful patient selection.
HE management concurrently: Lactulose titrated to 2–3 soft stools/day. Rifaximin if lactulose inadequate. Note that lactulose causes free water loss in stool, which can raise Na (via volume depletion and osmotic diarrhea).

Stage 4 · When to Escalate

Tolvaptan, Hypertonic Saline, and the Severe-Symptom Exception

Most cirrhotic / HF hyponatremia is chronic and mild. When symptoms become severe — encephalopathy attributable to Na, seizure, coma — the calculus shifts toward acute correction. The trap is over-corrections in patients with big effective-volume shifts ahead (e.g., LVAD implantation, post-transplant).

Click to expand escalation thinking ↓

Severe-symptom threshold: Coma, seizure, or HE grade 3–4 attributable to hyponatremia (difficult to parse in cirrhotics — always consider lactulose titration first, and check ammonia). If convinced Na is the driver, use 3% NaCl bolus 100 mL over 10 min, repeat up to 3 times, same as Journey 1 — but be prepared for rapid overcorrection when effective volume improves (post-albumin, post-paracentesis, post-TIPS, post-transplant).
Tolvaptan in hypervolemic hyponatremia: EVEREST (HF): no mortality benefit despite Na improvement. SALT-1/2 included HF and cirrhosis patients and showed Na improvement. Cirrhosis: FDA label warns against use due to hepatotoxicity signal — most hepatologists avoid tolvaptan in cirrhotics. HF Na <125 with severe symptoms: reasonable in-hospital bridge, <30 days.
The post-transplant overcorrection trap: When a cirrhotic with chronic hyponatremia (say Na 122) receives a liver transplant, the splanchnic vasodilation reverses, ADH drops off, and Na can rise 15–20 mEq/L in 24 hours. This is a classic ODS scenario. Pre-transplant centres often aim to raise Na gradually in the weeks before transplant (target >130) and use DDAVP peri-operatively to prevent overshoot.
Hypertonic saline — use cautiously: In cirrhotics, every mL of 3% NaCl (513 mEq Na/L) is also a huge sodium load that will expand ascites. If a bolus is needed for symptoms, give it in the smallest dose that resolves the symptom, then de-escalate to water restriction.

The "do less" principle In hypervolemic hyponatremia, accept Na 125–132 as a therapeutic goal. Do not chase 140. The additional risk of overcorrection, rebound ascites, and HRS from aggressive diuresis almost always outweighs the incremental benefit of a "normal" sodium.

Stage 5 · HRS-AKI

When the Kidney Joins the Fight — HRS-AKI and Terlipressin

Cirrhotic hyponatremia is often a warning shot. If Cr rises while Na is falling, you may be entering hepatorenal syndrome. The treatment converges on one idea: restore effective circulating volume.

Click to expand HRS management ↓

HRS-AKI diagnostic criteria (EASL / AASLD): Cirrhosis with ascites; Cr increase ≥0.3 mg/dL in 48 h or ≥50% from baseline in 7 days; no response to 48 h volume expansion with IV albumin 1 g/kg/day; no shock; no recent nephrotoxic drugs; no structural kidney disease (proteinuria <500 mg/day, no microhematuria, normal renal ultrasound).
Terlipressin (FDA-approved 2022): V1-selective vasopressin analogue. Splanchnic vasoconstriction → increased effective arterial volume → suppressed endogenous ADH/RAAS → improved renal perfusion. CONFIRM trial (Wong 2021): terlipressin + albumin reversed HRS-AKI in 32% vs 17% placebo. Adverse effects: bowel ischemia, respiratory failure, cardiac ischemia. Used as a bridge to transplant.
Alternative in settings without terlipressin: Norepinephrine in ICU (titrated to MAP increase 10–15 mmHg) + albumin. Less convenient but functionally similar. Midodrine + octreotide + albumin is an outpatient bridge with much weaker evidence.
Why Na often rises with HRS treatment: Restoring effective arterial volume suppresses non-osmotic ADH → free water excretion → Na rises. Closely monitor for overcorrection, especially pre-transplant.
Definitive treatment: Liver transplantation. HRS-AKI is usually reversible with a functioning graft. Renal recovery is expected in the majority of transplanted patients if HRS is <4–6 weeks duration.

Stage 6 · HFrEF version

Hyponatremia as a Prognostic Biomarker in Heart Failure

The same physiology plays out in severe HFrEF. Na is one of the most powerful free prognostic biomarkers available. Every GDMT pillar reduces neurohormonal drive and helps, but Na is also an independent signal that the pipeline of decompensation is open.

Click to expand HF-specific considerations ↓

Prognostic weight: OPTIMIZE-HF, ADHERE, COMET: Na <135 at admission predicts in-hospital and 1-year mortality independently of EF, age, and BNP. Every 3 mEq/L below 140 roughly corresponds to a 15–20% higher mortality hazard. It is also one of the few cheap, universally available prognostic data points.
Management in HF: Cornerstone: optimise GDMT. ARNI (sacubitril-valsartan) particularly reduces neurohormonal drive and often raises Na 2–3 mEq/L over weeks. SGLT2i (dapagliflozin, empagliflozin) adds mild osmotic water loss and modestly raises Na. Beta-blocker titration reduces sympathetic drive. MRA blocks aldosterone directly.
Loop diuretics and Na: High-dose loops can worsen hyponatremia by producing volume contraction → non-osmotic ADH → water retention. Sometimes paradoxically adding thiazide (metolazone) blocks DCT reabsorption and improves diuresis without worsening Na — but the evidence is patchy and bedside judgement is needed.
Hypertonic saline "kindling": Paterna 2011 and later small trials showed that small doses of hypertonic saline added to high-dose loop diuretics can break through diuretic resistance in advanced HF. Mechanism: raising plasma Na improves interstitial-to-intravascular fluid shifts and blunts neurohormonal drive. Not yet standard; emerging role.
When to consider LVAD / transplant: INTERMACS profile deterioration, recurrent HF hospitalizations, persistent Na <130 despite optimal GDMT and diuresis, RV failure, end-organ dysfunction. Hyponatremia that does not correct on full GDMT is a marker for advanced disease and should trigger referral to an advanced HF center.

Stage 7 · Outcomes

Prognosis in Hypervolemic Hyponatremia

In both cirrhosis and HF, hyponatremia is a late-stage signal. Na alone does not cause the mortality; it is a marker of the underlying illness severity. But correcting it where possible reduces symptom burden and may reduce hospital length of stay.

Click to expand outcomes data ↓

Cirrhosis mortality: Na <130 at MELD evaluation: MELD-Na score (incorporates Na; UNOS priority since 2016). 90-day waitlist mortality rises steeply below Na 130. 1-year post-transplant survival is good (80–85%) if transplant can be achieved.
HF mortality: OPTIMIZE-HF: Na <134 at admission doubled in-hospital mortality vs Na ≥136. Post-discharge 1-year mortality also 2-fold. EVEREST: correcting Na with tolvaptan did not improve mortality — consistent with "marker not mediator" interpretation for this intervention.
LVAD candidacy: Persistent Na <130 despite optimal therapy → INTERMACS 3–4 (declining on inotropes or recurrent hospitalizations) → indication for advanced therapies evaluation.
Symptomatic benefit of correction: Even if mortality does not change, correcting Na from 122 to 130 reduces subjective fatigue, improves cognition (HE component in cirrhosis), and may reduce hospital length of stay. These are legitimate goals in their own right.

Stage 1 · Presentation

The Vomiting Patient with Tachycardia — and Why Urine Na Matters

A 46-year-old woman with Crohn's disease on azathioprine presents after 5 days of nausea, vomiting (15–20 episodes), and watery diarrhea (she thinks she has the flu that "went around daycare"). BP 96/58, HR 112, Na 125, Cr 1.4 (baseline 0.7). She has been drinking tap water and Gatorade but "cannot keep anything down."

Click to expand the bedside picture ↓

The pattern: appropriate ADH True volume depletion causes appropriate non-osmotic ADH release. The kidney conserves Na avidly (urine Na <10 when losses are extra-renal) and water (urine osm high). Hyponatremia arises because the patient is replacing lost isotonic fluid with free water or hypotonic drinks — the ADH machinery keeps reabsorbing water faster than Na intake replaces the salt.

Exam: Dry mucous membranes, orthostasis (BP drops to 82/54 standing with HR 130), skin tenting, flat JVP, cool extremities, no edema. Weight 4 kg below baseline 1 week ago. Pale, sunken-eyed.
Labs: Na 125, K 3.0 (GI loss + concomitant alkalosis), Cl 88, HCO₃ 32 (contraction alkalosis from vomiting), Cr 1.4, BUN 42 (high — pre-renal), UA 9.8 (high — volume contraction). Urine Na <5, urine osm 620, urine K 58, urine Cl 12.
Interpretation: Hypovolemic hyponatremia with extra-renal losses. Low urine Na (<10) + high urine osm + dry exam + orthostatic drop = volume depletion with intact RAAS and ADH response. BUN:Cr >20 supports pre-renal. High HCO₃ from vomit = contraction alkalosis with chloride deficit.
Why urine Cl is low: When vomiting is ongoing: urine Cl <20 (chloride-responsive alkalosis — will correct with NS). Distinguishes from diuretic-induced or Cushing-related alkalosis (urine Cl >20, chloride-resistant).

Stage 2 · Urine-Na Algorithm

Renal vs Extra-Renal — The 20 mEq/L Divider

Within hypovolemic hyponatremia, the urine Na divides causes into two large buckets and changes the bedside move. Extra-renal loss → replete with saline. Renal loss → investigate the kidney or adrenal problem first.

Click to expand the algorithm ↓

Feature

Extra-renal losses

Renal losses

Urine Na

<10–20 mEq/L (avid reabsorption)

>20 mEq/L

Typical causes

Vomiting, diarrhea, NG suction, burns, pancreatitis, 3rd-spacing

Diuretics (thiazide, loop), osmotic diuresis (glucose, mannitol), cerebral salt wasting, salt-wasting nephropathy, mineralocorticoid deficiency

Urine osm

High (concentrated, >400)

Variable — depends on cause

BUN:Cr

>20

>20 initially; <20 if renal injury

Uric acid

Elevated

Variable

Response to NS

Na rises, symptoms improve — this confirms the diagnosis in retrospect

Depends — may need cause-specific therapy

The adrenal insufficiency fork in the road Primary adrenal insufficiency (Addison's) is a renal-loss hypovolemic hyponatremia because aldosterone deficiency causes Na wasting. Features: hyperkalemia (aldosterone-deficient K retention), hyperpigmentation, orthostasis, fatigue, hypoglycemia, eosinophilia. Any hypovolemic hyponatremia with hyperkalemia must have a random cortisol and a cosyntropin stim — missing it kills people. Secondary adrenal insufficiency (pituitary) also causes hyponatremia but via free-water retention (no CRH suppression of ADH); K is usually normal.

Extra-renal loss details: Vomiting: Loses HCl → contraction alkalosis; urine Cl <20. Diarrhea: Loses HCO₃ → non-anion-gap metabolic acidosis. NG suction: Similar to vomiting. Burns: Loses isotonic fluid; large insensible losses. Pancreatitis/peritonitis: Third-space sequestration — extra-cellular but not intravascular.
Renal loss details: Thiazide: Most common cause of drug-induced hyponatremia (see Journey 3). Loop: Less often causes hyponatremia (disrupts medullary gradient). Osmotic diuresis: Hyperglycemia (DKA/HHS correction phase), mannitol, glucose in urine. Cerebral salt wasting: Post-SAH, post-TBI — natriuresis driven by BNP. Treated with salt (opposite of SIADH).
The "Addisonian crisis" presentation: Shock, hypoglycemia, hyperpigmentation (primary), vomiting, abdominal pain, confusion, hyperkalemia, hyponatremia. Check random cortisol STAT (should be >18 in stress — if low, empiric hydrocortisone 100 mg IV while working up). Cosyntropin stim (250 μg IV, measure cortisol at 30 and 60 min — >18 normal response).

Stage 3 · Pathophysiology

Why the Kidney Retains Water When It Shouldn't

The cellular story is mostly downstream of a single decision the body made: preserve volume over preserve osmolality. Under threat of shock, the hypothalamus sends ADH; the adrenal zona glomerulosa sends aldosterone; the sympathetic nervous system constricts. All three conspire to keep circulating volume intact at the cost of hypotonicity.

Click to expand the cellular sequence ↓

Baroreceptor cascade: High-pressure carotid & aortic arch baroreceptors sense reduced stretch → reduced vagal tone → increased hypothalamic CRH, AVP → ADH release + ACTH → cortisol. Low-pressure baroreceptors (LV, LA, pulmonary veins) detect reduced filling → increased SNS + RAAS.
RAAS activation: Reduced renal perfusion → macula densa senses low NaCl delivery → renin release → Ang II (vasoconstriction + Na reabsorption via proximal tubule + aldosterone release) → aldosterone (increases ENaC and Na⁺/K⁺-ATPase in the collecting duct principal cells → Na retention, K wasting).
ADH cascade: Baroreceptor-driven ADH release bypasses the osmotic set-point. V2 receptor → cAMP → AQP2 trafficking → free water reabsorbed. If the patient then drinks hypotonic fluid (water, dilute juice, tea), the Na falls.
The "Gatorade isn't hypotonic enough" problem: Gatorade contains Na ~18 mEq/L, K ~3 mEq/L — total cations ~21 mEq/L, roughly 42 mOsm tonicity when you count accompanying anions (for the freely filterable portion; the rest is sugar). This is hypotonic to plasma. A patient with vomiting losing 100+ mEq/L of Na and replacing with Gatorade creates exactly the hypovolemic hyponatremia picture. Pedialyte is closer (Na ~45) but still hypotonic.
Why SIADH-pattern patients have low urine Na too (occasionally): In SIADH, urine Na is usually >30. But if a SIADH patient is strictly salt-restricted or has become mildly hypovolemic from a second process, urine Na can dip below 20 — the diagnostic distinction then requires a careful volume exam.

Stage 4 · Treatment

Isotonic Saline — and the Moment the ADH Turns Off

The primary treatment of hypovolemic hyponatremia is volume replacement with isotonic saline. The trap is that as volume is restored, ADH shuts off, the kidney dumps free water, and Na rises rapidly — often overshooting the safe ceiling.

Click to expand the detailed plan ↓

Resuscitation phase

0.9% NaCl 500 mL over 30 min, then 150 mL/hr

Targets: HR < 100, MAP > 65, skin warm, urine output > 0.5 mL/kg/hr, orthostasis resolved. For the index patient: expect 1.5–2 L in the first 6 hours.

Replete K (hypokalemia of GI loss plus alkalosis) — 20–40 mEq KCl added to each liter if no contraindication. Replete Mg. Ondansetron for nausea. Hold oral water intake until Na > 130 to avoid autocorrection.

The autocorrection overshoot — the single most important thing to anticipate Once effective volume is restored, non-osmotic ADH drive falls off. The kidney becomes free to excrete the excess free water. Urine osm drops precipitously (from 620 → <100), urine output surges, and Na climbs rapidly. Na can rise 10–15 mEq/L in 8 hours if not watched. Re-check Na every 2–4 hours during resuscitation, not every shift. When you see urine osm drop or a Na rise >6 mEq/L in 6 h, stop the saline and consider DDAVP 2 μg IV + D5W to clamp.

How much NS raises Na in hypovolemic hyponatremia: Each liter of NS (Na 154 mEq/L) in a patient with Na 125 provides Na at a concentration 29 mEq/L above the patient's serum. Plus it shuts off ADH → the kidney dumps liters of free water. Combined effect: ~3–6 mEq/L rise per liter of NS. Much faster than Adrogué–Madias predicts.
Rate limits still apply: ≤8 mEq/L rise per 24 h if any high-risk feature (hypokalemia, malnutrition, alcohol, age, Na <120). Our index patient has hypokalemia and Crohn's with some malnutrition → treat as high-risk and respect the 8 mEq/L ceiling.
If overshoot is happening: Switch from NS to D5W. Give DDAVP 2 μg IV (effect in 15 min; lasts 6–12 h). Re-check Na in 1 h. If rise continues, repeat DDAVP + add free water deliberately. The goal is to bring Na back into the corridor — re-lowering Na after over-rapid rise (Soupart, Adrogué) has been shown to reduce ODS risk in animal models and human case series.
Adrenal insufficiency variant: If the patient is Addisonian: give hydrocortisone 100 mg IV immediately (do not wait for cosyntropin stim). Cortisol replacement relieves non-osmotic ADH drive and the kidney can excrete free water. Aldosterone deficiency requires fludrocortisone 0.1 mg PO daily once stable. Saline resuscitation is adjunctive.

Stage 5 · Monitoring

The 2-Hour Rhythm — Catching the Turn

Hypovolemic hyponatremia has a predictable kinetic. Na drifts up slowly during resuscitation, then inflects sharply when ADH turns off (usually 4–12 h after volume restoration begins). Catching this inflection is the difference between a controlled correction and ODS.

Click to expand the monitoring plan ↓

Na timing: Baseline on admission. Check at 2, 4, 6, 8 h. Then q4h until stable >130 for two consecutive values.
Urine output and urine osm: Urine output hourly. Spot urine osm q4h during the first 24 h. Urine osm dropping from 620 → <200 is your alarm.
I/O balance: Track cumulative net input-output. During resuscitation, net positive by 1–2 L is expected. Once effective volume is restored, aim for net-even or slightly negative until Na is stable.
Clinical signs: Mental status, dry mucous membranes, orthostasis, skin turgor, HR trend. These should improve within 2–4 h of adequate resuscitation.
Electrolyte co-management: K q6h until >3.5. Mg q12h until >2.0. Phosphate daily if at risk for refeeding syndrome (chronically malnourished Crohn's patient on restrictive diet).

Stage 6 · Underlying Cause

Fix the Loss — and Plan for Recurrence

Replete, then address the cause. In this patient (viral gastroenteritis on a background of Crohn's), most of the work is anti-emetic, anti-diarrheal, and nutrition. In an Addisonian, it is lifelong replacement. In a thiazide-induced pattern, it is drug withdrawal.

Click to expand cause-specific management ↓

Gastroenteritis: Ondansetron for nausea, loperamide (cautiously — avoid if suspected C. difficile or bloody diarrhea). Send stool studies (O&P, culture, C. diff PCR, norovirus PCR if institutional). Oral rehydration with isotonic (WHO ORS: Na 75 mEq/L) once able to tolerate.
Crohn's consideration: Rule out active Crohn's flare (fecal calprotectin, CRP, cross-sectional imaging if clinically warranted). Continue azathioprine unless evidence of drug-induced pancreatitis or marrow suppression.
Adrenal insufficiency: If confirmed: hydrocortisone replacement (20 mg AM, 10 mg late afternoon typical). Fludrocortisone 0.1 mg daily if primary adrenal insufficiency. MedicAlert bracelet. Stress-dose steroid plan for illness/surgery (triple usual dose for 3 days or IV 100 mg q8h if severely ill).
Thiazide-induced (Journey 3 reference): Stop drug permanently, document as contraindicated.
CSW (post-neurological injury): Treat with salt (oral NaCl 2 g TID) and hypertonic saline if Na < 125. Fludrocortisone 0.1–0.3 mg/day has modest evidence. Resolves as the underlying neurological insult heals (days to weeks).

Stage 7 · Prognosis

What Happens Next

Uncomplicated hypovolemic hyponatremia from GI loss has an excellent prognosis if corrected carefully and the cause is transient. Addisonian hyponatremia with adrenal replacement also has excellent prognosis. The mortality lives in two places: missed adrenal insufficiency (Addisonian crisis) and ODS from over-rapid correction.

Click to expand outcomes ↓

GI-loss hyponatremia mortality: In the absence of missed diagnoses and without overcorrection, <1% in-hospital mortality. Most patients are normal by day 3.
ODS risk: High-risk (Na <120, K <3, alcohol, malnutrition, female): if corrected at ≤8 mEq/L in 24 h, ODS rate <1%. If corrected >12 mEq/L in 24 h, ODS rate 5–10% (historical series). This is why the 2-hour Na rhythm matters.
Addisonian crisis mortality: Previously >20%. With modern recognition (random cortisol, stim testing, empiric steroids), <5%. Missed diagnosis remains the dominant mortality driver — when it is missed and patients are given saline without steroid, they often continue to deteriorate.
Recurrence: Transient cause (gastroenteritis): very low unless recurrent IBD flares. Chronic cause (Addison's, chronic GI loss, recurrent pancreatitis): high — ongoing prophylaxis, patient education, wallet card.